Myrtelle
Debaditya Bhattacharya, Ph.D., is a seasoned expert in the fields of CMC strategy, product development, and analytical operations within the biotechnology sector. Currently serving as a Consultant at Myrtelle since April 2025, Debaditya previously held notable leadership roles including Vice President at ElevateBio, overseeing analytical CMC from December 2022 to March 2025, and Senior Director at CRISPR Therapeutics, where a team of 30 was built for the characterization of CAR-T drug products. With prior experience at bluebird bio and Aura Biosciences in analytical and product development, respectively, and a solid foundational education culminating in a Ph.D. from Tufts University, Debaditya possesses a comprehensive background in molecular biology, biotechnology, and strategic operational leadership in the development of innovative therapeutics.
This person is not in any teams
This person is not in any offices
Myrtelle
Myrtelle is a gene therapy company that offers clinical trials for the treatment of rare monogenetic disorders. It helps in addressing an array of diseases with white matter involvement that includes demyelinating diseases and ASPA-associated disorders with rare CNS diseases. It also helps healthcare professionals to develop and deliver noveltreatments for devastating disorders of the central nervous system and transform the treatment of neurological diseases that improve the quality of life and longevity.The company's mission is to develop and deliver novel treatments for devastating disorders of the central nervous system, beginning with its lead program, gene therapy treatment for Canavan disease.It was founded in 2020 and is headquartered in Wakefield, Massachusetts.